Calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways. Our investigational onco-metabolism approach takes advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. Calithera is developing a glutaminase inhibitor currently in two randomized Phase 2 renal cell carcinoma trials and in a Phase 2 triple negative breast cancer trial. We are also developing an oral arginase inhibitor, and a pipeline of novel tumor metabolism candidates.